Linezolid antimicrobial-lock solution — Competitive Intelligence Brief

Linezolid antimicrobial-lock solution (Linezolid antimicrobial-lock solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oxazolidinone antibiotic. Area: Infectious Disease.

marketed Oxazolidinone antibiotic Bacterial 50S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Linezolid antimicrobial-lock solution (Linezolid antimicrobial-lock solution) — Clinica Universidad de Navarra, Universidad de Navarra. Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and bacterial growth.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Linezolid antimicrobial-lock solution TARGET	Linezolid antimicrobial-lock solution	Clinica Universidad de Navarra, Universidad de Navarra	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
FMS azithromycin tablets	FMS azithromycin tablets	University of Taubate	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Administration of Azithromycin on Day 1	Administration of Azithromycin on Day 1	London School of Hygiene and Tropical Medicine	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
AzaSite®	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Clarithromycin (ST14)	Clarithromycin (ST14)	National Taiwan University Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 1gm	Azithromycin 1gm	Ain Shams Maternity Hospital	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Tedizolid PO	Tedizolid PO	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oxazolidinone antibiotic class)

1. Fundacion Clinic per a la Recerca Biomédica · 2 drugs in this class
2. University of Southern California · 2 drugs in this class
3. Arpida AG · 2 drugs in this class
4. Pfizer · 1 drug in this class
5. Shenzhen Third People's Hospital · 1 drug in this class
6. Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
7. Wuhan Pulmonary Hospital · 1 drug in this class
8. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
9. Merck Sharp & Dohme LLC · 1 drug in this class